Nurse Practitioner Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Harmony Hopkins

Nurse Practitioner, Family Agawam, MA Nurse Practitioner

NPI 1922522895 CMS profile 10976512

200 Silver St Unit 106, Agawam, MA 01001

Open in the dashboard

General payments

$14,421

640 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Harmony Hopkins of Agawam, MA is reported in the CMS Open Payments database as having received $14,421 across 640 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,097 254
2024 General $4,361 194
2023 General $3,919 158
2022 General $1,044 34

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Harmony Hopkins
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Harmony Hopkins were reported at $5,097. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Harmony Hopkins Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $0 $124 $35–$379 $132
2022 $1,044 $141 $44–$430 $149
2023 $3,919 $154 $49–$476 $160
2024 $4,361 $165 $51–$504 $164
2025 $5,097 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. AbbVie, Inc. $2,564 119 payments
  2. UCB, Inc. $1,249 67 payments
  3. Novartis Pharmaceuticals Corporation $1,188 59 payments
  4. Lilly USA, LLC $1,154 41 payments
  5. Janssen Biotech, Inc. $982 40 payments
  6. Genzyme Corporation $895 25 payments
  7. Amgen Inc. $802 22 payments
  8. Sun Pharmaceutical Industries Inc. $762 31 payments
  9. Regeneron Healthcare Solutions, Inc. $722 23 payments
  10. Arcutis Biotherapeutics, Inc. $719 43 payments
  11. Other $3,384 170 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $14,004 633 payments
  2. Education $417 7 payments
Products named General payments · program years 2022–2025
  1. DUPIXENT $1,343 38 payments
  2. RINVOQ $1,335 43 payments
  3. TREMFYA $1,131 41 payments
  4. Bimzelx $1,037 56 payments
  5. COSENTYX $915 49 payments
  6. TALTZ $821 33 payments
  7. Otezla $802 22 payments
  8. SKYRIZI $775 35 payments
  9. SOTYKTU $718 37 payments
  10. OLUMIANT $660 22 payments
  11. Other $6,295 315 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

447

Median for Nurse Practitioner: 389

Drug cost

$319,871

Median for Nurse Practitioner: $21,885

Branded share of claims

9.2%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 13 $151,452
Cosentyx Sensoready (2 Pens) Secukinumab Brand 12 $93,216
Dupixent Pen Dupilumab Brand 16 $59,258
Tacrolimus Generic 27 $3,977
Fluocinonide Generic 46 $2,338
Alclometasone Dipropionate Generic 26 $1,480
Ketoconazole Generic 69 $1,292
Triamcinolone Acetonide Generic 81 $1,233
Calcipotriene Generic 15 $1,163
Clobetasol Propionate Generic 21 $1,105

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 22 billing codes

Paid by Medicare

$29,808

Medicare's payments for the services billed

Medicare patients

318

Average age 72

Services billed

765

178 women, 140 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 45%
Diabetes 25%
Depression 23%
Chronic kidney disease 21%
Ischemic heart disease 17%
COPD 14%
Cancer 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
  • AbbVie, Inc. $557
$557 — —
Bimzelx
  • UCB, Inc. $420
$420 — —
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $384
$384 — —
Zoryve
  • Arcutis Biotherapeutics, Inc. $312
$312 — —
COSENTYX
  • Novartis Pharmaceuticals Corporation $279
$279 12 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

640 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record